X Facebook LinkedIn WhatsApp Press Releases (-) Any 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2013 November 3, 2013 arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B September 18, 2013 arGEN-X reaches milestone in SIMPLE Antibody™ research and product development collaboration with Shire September 16, 2013 arGEN-X initiates Phase Ib study of ARGX-111 in cancer September 11, 2013 arGEN-X identifies potent antibody antagonists against complex chronic pain target Nav1.7 August 5, 2013 arGEN-X grants license to its NHance™ antibody half-life extension technology April 25, 2013 arGEN-X to Present at Upcoming Ninth Annual PEGS 2013 March 24, 2013 arGEN-X announces preclinical development of ARGX-112 for dermatology January 6, 2013 arGEN-X initiates Phase Ib study of ARGX-110 in cancer January 6, 2013 arGEN-X expands its therapeutic antibody alliance with Shire 2012 December 5, 2012 arGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform November 5, 2012 arGEN-X reveals the target and unique mechanism of action of its most advanced preclinical antibody at the PEGS Summit 2012 October 24, 2012 arGEN-X appoints Dr. David L. Lacey to its supervisory board Pagination First page « First Previous page ‹ Previous … Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Current page 31 Page 32 Page 33 Next page Next › Last page Last »
